In this study, the 10-year survival rate for female breast cancer patients with a PALB2 mutation was 48.0% (95% CI, 36.5–63.2), significantly lower than that for PALB2 mutation-negative female breast cancer patients (74.7%; 95% CI, 73.5–75.8). The gene discussed is PALB2; the disease is breast carcinoma.